Welcome to AtriAN

AtriAN Medical

Restoring Rhythm through Science

Mission & Vision

Resolving Atrial Fibrillation at its origin

Current therapies are failing patients and their physicians. Medication fails 70% of the time, and ablations fail 30% within the first year and 50% within three. We are targeting the cardiac autonomic nervous system which should lead to a more durable solution significantly reducing the need for repeat procedures.

TECHNOLOGY

A Disruptive Approach to Rhythm restoration

First, we navigate to the heart’s epicardial (outside) surface, where the errant signals originate in specialized neurons. Secondly, we use new and non-thermal energy (PFA) to disable the neurons permanently.

THE DISRUPTION

AtriAN’s Business Pathway

Growing Market

Atrial Fibrillation is a large and quickly growing condition. Unfortunately, there is yet to be a perfect solution for its resolution. AtriAN’s mission is to change this for patients and their physicians.

Robust and Innovative Intellectual Property (IP)

The idea and technology were conceived and first developed at the Mayo Clinic (Rochester, MN, USA) by Dr. Sam Asirvatham with issued patents across the globe. We continue to innovate the technology.

Unique Solution

AtriAN takes a novel and unique approach to the resolution of the disease by targeting and disabling the hyperactive signals responsible for the arrhythmia.

Funding in Place

AtriAN has raised over €5M in funding, bringing us to that exciting stage of first clinical treatments. We are seeking expressions of interest from investors for the next phase of our journey.

Unmet Need

Existing medications have a very high failure rate and affect every organ in the body. Current ablation technologies only seek to block the signals responsible for this condition; this results in recurrence rates that are far too high.

First In Human (FIH) Trials

AtriAN is excited to announce that we have enrolled and treated 36 patients in two First-In-Human (FIH) trials.

Clinical Trials

In addition to our work with Pulsed Field Ablation (PFA), we are progressing our R&D with innovative, unique and minimally-invasive catheters to reach and deliver the energy to the epicardial surface of the heart.

Pulsed Field Ablation (PFA)

This energy is revolutionising the field of electrophysiology due to its safety profile. While most companies replace thermal energy with PFA, on the inside of the heart (endocardial) AtriAN takes it directly to the condition’s origin on the outside (epicardially).

Autonomics Remodeling

Neuromodulation has been one of the most exciting and disruptive approaches to medicine in recent years. Our approach is to restore the autonomic tone of the heart by targeting and disabling the ganglionated plexi (GP) structures.

Sub-Xiphoid Approach

We are using a unique, small incision in the sub-xiphoid region using our small IP-protected catheters.

GENTLE, NON-THERMAL ENERGY

Pulsed Field Cardioneuroablation

AtriAN selectively targets the hyperactive ganglionated plexi (GPs) located on the outside (epicardial) surface of the heart, rebalancing the autonomic tone bringing the heart back to its natural rhythm.
N

Selectively targets and disables the GPs

N

Gently spares the myocardium (heart muscle).

Gentle

AtriAN uses Pulsed Field Ablation (PFA) to ablate neuronal cells selectively.
As a result, the other tissues, such as healthy heart muscle, are spared.

Non-Thermal

Most ablation techniques use either heat (burning) or cold (freezing) to ablate tissue with an intent to create scar tissue which damage surrounding healthy tissues. Our PFA is non-thermal.

Long-Term

Our unique approach of targeting neuronal cells in clusters known as ganglionated plexi (GPs) should prove, from a “first principles” approach to provide a more durable solution.
Catheters

Unique, IP-Protected Catheters

Our unique and patent-protected catheter designs ensure excellent field coverage using saline-infusion while also ensuring navigation to the local sites.

Our Team

AtriAN team members

Publications

Pulsed Electric Field Ablation of Epicardial Autonomic Ganglia: Computer Analysis of Monopolar Electric Field across the Tissues Involved

Electric Field Models
A González-Suárez, B O’Brien, M O’Halloran et al
Bioengineering 2022

This electric field modelling study assessed the field strength distribution in the epicardial fat pads (where the ganglionated plexi are located) and the underlying myocardium, when monopolar pulses are applied. The field strength tends to concentrate within the fat layer, with a substantial drop off into the myocardium. This effect further explains the observed selectivity of ganglia ablation when the treatment is performed epicardially.

In Silico Modelling to Assess the Electrical and Thermal Disturbance Provoked by a Metal Intracoronary Stent during Epicardial Pulsed Electric Field Ablation

Electric Field Models
A González-Suárez, J Perez, B O’Brien et al
J. Cardiovasc. Dev. Dis. 2022
The effect of a metallic coronary stent within the applied electric field was modelled in this study. Electrical field distortions and thermal effects were assessed. The presence of a stent causes minor electric field disruption, leading to increased field concentrations at the stent and a resulting localized temperature increase. This increase was insignificant and not at a level that would cause tissue damage or necrosis.

News

contact us

Get In Touch

We would love to hear from you. Reach out anytime.

Address

Unit 1,
BIC Centre
Upper Newcastle
Galway Ireland
H91E79C

Visit

Visit us in Galway

Unit 1 (Physical), H91E79C
Unit 204 (Billing), H91W60E

Atrian

Unit 1, BIC Centre
Upper Newcastle
Galway, Ireland
H91E79C
This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under Grant No. 879499.